Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted- infusion fluorouracil and weekly leucovorin

Journal of Clinical Oncology

Volumn 15, Issue 10, 1997, Pages 3223-3229

  Leichman, Cynthia Gail ^a   Lenz, Heinz Josef ^a   Leichman, Lawrence ^a   Danenberg, Kathleen ^a   Baranda, Joaquina ^a   Groshen, Susan ^a   Boswell, William ^a   Metzger, Ralf ^a   Tan, Matthew ^a   Danenberg, Peter V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; FLUOROURACIL; FOLINIC ACID; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME SYNTHESIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030883708     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.10.3223     Document Type: Article

References (34)

1. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA Cancer J Clin 45:8-11, 1995
2. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1404-1417, 1989
3. Ardalan B, Singh G, Silberman H, et al: A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without n-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6:1053-1058, 1988
4. Wadler S, Schwartz EL, Goldman M, et al: Fluorouracil and recombinant alfa-2-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 7:1769-1775, 1989
5. Hill M, Norman A, Cunningham D, et al: Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 13:1297-1302, 1995
6. Leichman CG, Fleming TR, Muggia FM, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13:1303-1311, 1995
7. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
8. Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991
9. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Superiority of sequential methotrexate, fluorouracil and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial. J Clin Oncol 7:1437-1446, 1989
10. Berger SH, Hakala MT: Relationship of DUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol 25:303-309, 1984
11. Spears CP, Shahinian AH, Moran RG, et al: In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and resistant murine colon adenocarcinomas. Cancer Res 42:450-456, 1982
12. Washtien WL: Thymidylate synthase levels as a factor in 5-fluorodeoxyuridine and methotrexate cytotoxicity in gastrointestinal tumor cells. Mol Pharmacol 21:723-728, 1982
13. Chu E, Drake JC, Koeller DM, et al: Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 39:136-143, 1990
14. Berger SH, Jer CH, Johnson LF, et al: Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 28:461-467, 1985
15. Swain SM, Lippman ME, Egan EF, et al: Fluorouracil and high dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7:890-899, 1989
16. Peters GJ, van Groeningen CJ, Laurensse EJ, et al: Thymidylate synthase from untreated human colorectal cancer and colonie mucosa: Enzyme activity and inhibition by 5-fluoro-2′-deoxy-uridine-5′-monophosphate. Eur J Cancer 27:263-267, 1991
17. Spears CP, Waugh W, Leichman L, et al: Salvage therapy of breast cancer with fluorouracil (5-FU) and high-dose leucovorin (LV): Response correlates with tumor pharmacodynamics. Proc Am Soc Clin Oncol 9:73, 1990 (abstr)
18. Takeishi K, Kaneda S, Ayusawa D, et al: Nucleotide sequence of a funtional cDNA for human thymidylate synthase. Nucleic Acids Res 13:2035-2045, 1987
19. Eisenstein BI: The polymerase chain reaction: A new method of using molecular genetics for medical diagnosis. N Engl J Med 322:181-183, 1990
20. Leichman CG, Leichman L, Spears CP, et al: Biochemical modification of protracted infusion of 5-fluorouracil with weekly leucovorin: A dose-seeking clinical trial in patients with disseminated gastrointestinal cancers. Cancer Chemotherapy Pharmacol 26:57-61, 1990
21. Leichman CG, Leichman L, Spears CP, et al: Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: A phase II study in patients with colorectal cancer. J Natl Cancer Inst 85:41-44, 1993
22. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
23. Horikoshi T, Danenberg KD, Stadbauer THW, et al: Quantitation of thymidylate synthase dihydrofolate reductase and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 52:108-116, 1992
24. Lenz H-J, Danenberg KD, Leichman L, et al: Quantitation of thymidylate synthase gene expression using PCR and centrifugal Sephadex columns. PCR Meth Appl 4:305-308, 1995
25. Johnston PG, Lenz H-J, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-1412, 1995
26. Lenz H-J, Leichman CG, Danenberg KD, et al: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 14:176-182, 1996
27. Kuo DY, Mallick S, Shen HJ, et al: Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry. Clin Cancer Res 2:1981-1992, 1996
28. Takeishi K, Kaneda S, Ayusawa D, et al: Nucleotide sequence of a functional cDNA for human thymidylate synthase. Nucleic Acids Res 13:2035-2045, 1987
29. Ng S-Y, Gunning P, Eddy R, et al: Evolution of the functional β-actin gene and its multipseudogene family: Conservation of non-coding regions and chromosomal dispersion of pseudogenes. Mol Cell Biol 5:2720-2732, 1985
30. Leichman L, Lenz HJ, Leichman CG, et al: Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial. Eur J Cancer 31A:1306-1310, 1995
31. Miller R, Siegmund D: Maximally selected chi square statistics. Biometrics 38:1011-1016, 1982
32. Halpern J: Maximally selected chi square statistics for small samples. Biometrics 38:1017-1023, 1982
33. Izzo J, Zarba J, Rougier P, et al: Low dose continuous infusion (FUCI) in advanced colorectal cancer: Clinical evidence for reversal of acquired/intrinsic resistance to 5 FU or 5 fufolinic (FuFo). Proc Am Assoc Cancer Res 33:1298, 1992 (abstr)
34. Campbell FC, Elston CW, Blarney RW, et al: Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 2:1317-1319, 1981